Search

Displaying results 6301 - 6310 of 7604 in total
  1. Drug

    GDC-0349

    go.drugbank.com/drugs/DB13072
    Investigational

    GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.

  2. Drug

    HM15912

    go.drugbank.com/drugs/DB18266
    Investigational

    HM15912 is a human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment.

  3. Drug

    Gambir

    go.drugbank.com/drugs/DB14298
    Investigational

    It is not an approved drug.

  4. Drug

    Pomegranate

    go.drugbank.com/drugs/DB14317
    Investigational

    It is not an approved drug.

  5. Drug

    Rocacetrapib

    go.drugbank.com/drugs/DB15437
    Investigational

    Rocacetrapib is under investigation in clinical trial NCT02156544 (Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519).

  6. Drug

    STC3141

    go.drugbank.com/drugs/DB16475
    Investigational

    STC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.

  7. Drug

    Sigvotatug Vedotin

    go.drugbank.com/drugs/DB18377
    Investigational

    Sigvotatug vedotin (SGN-B6A) is a humanized immunoglobulin G1 anti-integrin beta-6 monoclonal antibody conjugated to monomethyl auristatin E.

  8. Drug

    Mizagliflozin

    go.drugbank.com/drugs/DB19036
    Investigational

    Mizagliflozin is under investigation in clinical trial NCT05721729 (Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions).

  9. Drug

    Honokiol

    go.drugbank.com/drugs/DB19283
    Investigational

    Honokiol is under investigation in clinical trial NCT00966953 (Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.).

  10. Drug

    Indium In-111

    go.drugbank.com/drugs/DB11916
    Investigational

    Indium In-111 is under investigation in clinical trial NCT00493454 (Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas).